Company Snapshot: Retrophin, Inc.
Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, New York-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin has begun enrollment in a potentially pivotal Phase 2 clinical trial of its lead compound, sparsentan, for FSGS. The Company also intends to reintroduce Syntocinon Nasal Spray (oxytocin) in the U.S. to assist initial postpartum milk ejection and also initiate clinical trials for the drug as a potential treatment for schizophrenia and autism. Retrophin plans to initiate a Phase 1 pharmacokinetic trial of RE-034, an ACTH analog, in the first half of 2014.
- Jan 8 2018 Retrophin Provides Corporate Update and 2018 Outlook
- Jan 5 2018 Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)
- Dec 28 2017 Retrophin to Present at the 36th Annual J.P. Morgan Healthcare Conference
- Nov 30 2017 Retrophin to Present at the BMO 2017 Prescriptions for Success Healthcare Conference